title: Reply to C.G. Azzoli et al and C. Chouaid et al.
authors.affiliation: Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada Natasha.Leighl@uhn.ca.
authors.forename: Natasha B
authors.initials: NB
authors.lastname: Leighl
authors.affiliation: Cancer Care Ontario, Toronto, Ontario, Canada.
authors.forename: Jaclyn M
authors.initials: JM
authors.lastname: Beca
authors.affiliation: Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
authors.forename: Ming-Sound
authors.initials: MS
authors.lastname: Tsao
authors.affiliation: Cancer Care Ontario, Toronto, Ontario, Canada.
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Hoch
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics*; D014408:Biomarkers, Tumor / Q000032:analysis*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000191:economics*; D006801:Humans; D007150:Immunohistochemistry / Q000191:economics*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000191:economics*; D015514:Oncogene Proteins, Fusion / Q000032:analysis*; D011720:Pyrazoles / Q000191:economics*; D011725:Pyridines / Q000191:economics*
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D015514:Oncogene Proteins, Fusion; D011720:Pyrazoles; D011725:Pyridines